Logo Geneseeq
  • Services
    • Genomic Testing
      • Laboratory Developed Tests (LDT)
        • Solid Tumors
        • Hematologic Malignancies
        • Hereditary Cancers
        • Minimal Residual Disease
      • IVD Kit Solution
      • RUO Kit Solution
    • Research Services
      • Platforms
      • DNA Sequencing
      • RNA Sequencing
      • Other Services
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
  • Join Us
  • Contact Us
  • Ch|中文
  • Search

Geneseeq

October 17, 2023

Geneseeq to present four studies at ESMO 2023

0 Comments1 Minute

October 13, 2023

GENESEEQ RECEIVES CHINESE NMPA APPROVAL FOR LUNG CANCER TUMOR MUTATIONAL BURDEN NGS TEST KIT

0 Comments1 Minutes

August 29, 2023

GENESEEQ TO SHARE EIGHT COLLABORATED STUDIES AT WCLC 2023

0 Comments1 Minutes

August 22, 2023

Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer

0 Comments3 Minutes

May 25, 2023

GENESEEQ TO SHOWCASE NEW FINDINGS AT ASCO 2023

0 Comments2 Minutes

May 16, 2023

Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer

0 Comments2 Minutes

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info.toronto@geneseeq.com

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2023 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences